ArticleTranslational oncology2026
Machine learning and multi-omics analyses reveal CLDN1 as a candidate marker associated with colorectal cancer invasion and nutlin-3a (-) response.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveColorectal cancer (CRC) is molecularly, cellularly and spatially heterogeneous, and current staging systems and biomarkers incompletely explain prognosis and treatment response. This study integrated transcriptomics, machine learning, single-cell RNA sequencing, spatial transcriptomics and in vitro experiments to prioritize candidate CRC-associated markers and characterize their potential biological and clinical relevance.
methodsGSE44861 and GSE44076 from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas Colon Adenocarcinoma (TCGA-COAD) were used for differential expression, consensus differentially expressed gene (DEG) identification and functional enrichment analyses. Four machine-learning algorithms were applied for feature selection. Candidate genes were prioritized by differential expression, model importance and receiver operating characteristic (ROC) performance. GSE231559 single-cell data and spatial transcriptomics characterized the cellular source, pseudotime dynamics and spatial distribution of the core gene. TCGA-COAD assessed prognosis, pathways and computationally predicted drug sensitivity. Western blotting, Transwell and MTT assays were used for experimental validation, and public immunohistochemistry images from the Human Protein Atlas were used as supplementary protein-expression evidence.
resultsWe identified 544 consensus DEGs enriched in leukocyte migration, chemotaxis, extracellular matrix organization, cytokine activity and metabolic pathways. Six genes were jointly selected: CLDN1, CDH3, KRT24, MMP7, NEBL and SCGN. CLDN1 was markedly upregulated and showed the highest tumour-versus-normal discrimination among the six candidates in the TCGA-COAD cohort. Single-cell and spatial analyses showed that CLDN1 was mainly expressed in CRC epithelial cells, displayed increasing expression across the inferred pseudotime ordering, and was enriched in malignant and mixed regions. In the TCGA-COAD cohort, high CLDN1 expression was associated with poorer overall survival and pathways involving the cell cycle, proteasome, autophagy, Hippo, ErbB and CRC. CLDN1 manipulation altered CRC-cell invasion and in vitro response to Nutlin-3a (-).
conclusionThese findings support CLDN1 as a candidate CRC-associated marker linked to malignant epithelial-cell states, tumour-associated spatial heterogeneity, invasive phenotype and Nutlin-3a (-) response. Further independent and prospective validation is required to determine its clinical diagnostic, prognostic and treatment-response relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.